ACB - 22nd Century Group Aurora Cannabis And Cronos Group Set Sights On Cannabinoid Biosynthesis
- 22nd Century and Aurora Cannabis made an agreement with Cronos Group to license their cannabinoid biosynthesis intellectual property.
- The agreement aims to scale up the production and development of rare cannabinoids like CBN, CBG, and CBC.
- There is competition from other cultured cannabinoid producers like Amyris and BioHarvest Sciences.
- I rate 22nd Century Group as a Hold for now and recommend that investors watch the company’s developments.
For further details see:
22nd Century Group, Aurora Cannabis And Cronos Group Set Sights On Cannabinoid Biosynthesis